International Clinical Trial: A Phase II, Single-Arm Clinical Trial Evaluating the Safety and Efficacy of Golixitinib Addition in Patients with Peripheral T-Cell Lymphoma Demonstrating Suboptimal Response at Interim Assessment of First-Line Therapy

Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ChiCTR2600131819) titled 'A Phase II, Single-Arm Clinical Trial Evaluating the Safety and Efficacy of Golixitinib Addition in Patients with Peripheral T-Cell Lymphoma Demonstrating Suboptimal Response at Interim Assessment of First-Line Therapy' on Sept. 7.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: The First Affiliated Hospital of Nanjing Medical University

Condition: Peripheral T-cell lymphoma

Recruitment Status: Recruiting

Phase: 1-2

Date of First Enrollment: 2025-11-04

Target Sample Size: Experimental group:42;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn...